Detail of "19327-38-9"

Reference

Doubly virus-inactivated human blood plasma, blood plasma derivatives produced therefrom, and method for their production

Doubly virus-inactivated human blood plasma, blood plasma derivatives produced therefrom, and method for their production. Faucompre, Annick; Woeber, Guenter (Blutspendedienst der DRK-Landesverbaende Nordrhein und Westfalen-Lippe GmbH; Faucompre, Annick; Woeber, Guenter, Germany). PCT Int. Appl. WO 9704815 A1 13 Feb 1997, 18 pp. DESIGNATED STATES: W: AU, CA, CZ, FI, HU, JP, NO, NZ, PL, RO, RU, SK, US; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (German). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61L002-18. ICS: A61L002-04; A61K035-16. APPLICATION: WO 1995-EP4309 3 Nov 1995. PRIORITY: DE 1995-19528221 1 Aug 1995. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) A virally safe therapeutic biol. prepn. from human plasma which retains 350% of the biol. activity of native plasma is prepd. using a detergent, the detergent being removed at the end of the virus inactivation. Nonionic surfactants, whose mol. structure comprises a hydrophobic part consisting of a linear C8-10 aliph. chain, are used as detergents. The detergent treatment can be followed by a heat treatment, optionally using conventional stabilizers. The method is effective against both membrane-encapsulated viruses and those lacking a lipid membrane. Thus, pseudorabies virus, added exptl. to 50 mL plasma, was completely inactivated by addn.In this experiment, several chemicals are used like 19327-38-9 and 85316-98-9 of 0.5 g 1-thio-n-octyl-b-glucopyranoside and incubation at room temp. for 15 min. .